42nd week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110256138 | AMYLOID-BETA BINDING PROTEINS - The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided. | 2011-10-20 |
20110256139 | Therapeutic Uses Of Monoclonal Antibodies To The Angiotensin-II Type 1 Receptor - The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGHRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation. | 2011-10-20 |
20110256140 | ANTI-HCV MONOCLONAL ANTIBODY AS A MEDICAMENT FOR THE THERAPUTIC TREATMENT AND PREVENTION OF HCV INFECTIONS - The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents. | 2011-10-20 |
20110256141 | Monoclonal Antibodies Specific to the Fusion Peptide From Hemagglutinin From Influenza A Viruses and Uses Thereof - This invention relates to methods and products for the diagnosis, surveillance, prevention, and treatment of influenza A virus infections in animals and humans. More particularly, the invention relates to antibodies and related binding proteins for the detection, prevention and treatment of influenza A viruses. The monoclonal antibodies and related binding proteins of the invention are useful for the treatment of the highly pathogenic H5 subtypes of avian influenza virus (AIV). | 2011-10-20 |
20110256142 | NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER - The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein—said first antibody binds EGFR, —said second antibody binds EGFR, —said first and second antibody are non-cross-blocking, and—the dosage regimen is such that CDC is obtained at the tumor site. | 2011-10-20 |
20110256143 | FDF03 Antibodies and uses thereof - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 2011-10-20 |
20110256144 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCERS - The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids. | 2011-10-20 |
20110256145 | Connective Tissue Growth Factor-3 (CTGF-3) - The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods for detecting and treating connective tissue related disorders. | 2011-10-20 |
20110256146 | NEUROPILIN ANTAGONISTS - Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications. | 2011-10-20 |
20110256147 | DIAGNOSTIC AND TREATMENT METHODS FOR CANCER BASED ON IMMUNE INHIBITORS - Methods of diagnosis and treatment of malignant tumors, in particular ovarian tumors, using GD3 and GD3 inhibitors. Also provided are methods of modulating the immune system of a mammal by the administration of a GD3 and GD3 inhibitors. | 2011-10-20 |
20110256148 | Methods for Treating Hypercholesterolemia Using Antibodies to PCSK9 - The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof. | 2011-10-20 |
20110256149 | ANTIBODY FORMULATION - The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide The formulation provides for an anti-13H5 anti-human interferon alpha antibody A pre-filled syringe containing the formulation is also disclosed. | 2011-10-20 |
20110256150 | Modulation of Axon Degeneration - The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons. | 2011-10-20 |
20110256151 | ANTIBODIES TO HUMAN IL-1BETA - An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides. | 2011-10-20 |
20110256152 | Methods Of Treating And Preventing Glucose Toxicity - The present invention relates to a method for treating and/or preventing a disease associated with glucose toxicity in a subject which may comprise administering to the subject a compound that reduces the level of Bim, PUMA and/or Bax activity in a cell of the subject. Furthermore, provided is a method for culturing cells susceptible to exposure to high concentrations of glucose, which may comprise delivering to the cells, or progenitor cells thereof, a compound that reduces the level of Bim, PUMA and/or Bax activity in the cells. | 2011-10-20 |
20110256153 | CD37-Binding Molecules and Immunoconjugates Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided. | 2011-10-20 |
20110256154 | ANTI-ERBB3 ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3. | 2011-10-20 |
20110256155 | METHODS TO MOLECULARLY CHARACTERIZE CIRCULATING TUMOR CELLS - The invention relates to a rapid, sensitive method to obtain a gene expression profile from a target cell population in a blood sample. The target cells can be circulating tumor cells. Disclosed are methods and kits for obtaining such profiles. | 2011-10-20 |
20110256156 | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided. | 2011-10-20 |
20110256157 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer. | 2011-10-20 |
20110256158 | NOVEL USE OF AN IL-12 RECEPTOR SPLICE VARIANT AND MOLECULAR ASSAY TO QUANTIFY EXPRESSION THEREOF - The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a vaccine formulation comprising an antigen and IL12Rβ1 isoform 2. In some embodiments, this invention relates to a method of quantifying the ratio of IL12Rβ1 transcript and a splice variant thereof in a sample, including but not limited to at the cDNA level. In other embodiments, this invention relates to a method of augmenting an immune response by administering, inhibiting and/or inducing IL12Rβ1 isoform 2. | 2011-10-20 |
20110256159 | ADHERENT CELLS FROM PLACENTA TISSUE AND USE THEREOF IN THERAPY - A method of culturing adherent cells from a placenta or adipose tissue is disclosed. The method comprising culturing the adherent cells from the placenta or adipose tissue under 3 dimensional (3D) culturing conditions which allow cell expansion, the conditions comprising perfusion. | 2011-10-20 |
20110256160 | ADHERENT CELLS FROM PLACENTA TISSUE AND USE THEREOF IN THERAPY - A method of culturing adherent cells from a placenta or adipose tissue is disclosed. The method comprising culturing the adherent cells from the placenta or adipose tissue under 2 dimensional (2D) culturing conditions which allow cell expansion, the conditions comprising continuous passaging of the cells for at least 4 passages. | 2011-10-20 |
20110256161 | METHODS FOR ENHANCING IMMUNE RESPONSE - This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (PBT) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction. This therapeutic approach is equally applicable to disease states whereby immune system suppression by polyamines has been demonstrated including; bacterial infections, parasitic infections including malaria and typanosomiasis, viral infections, peptic ulcers and gastric cancer due to | 2011-10-20 |
20110256162 | PLASMIDS CODING FOR P185NEU PROTEIN SEQUENCE VARIANTS AND THERAPEUTIC USES THEREOF - DNA plasmids containing sequences coding for different fragments of 185 | 2011-10-20 |
20110256163 | IDENTIFICATION, OPTIMIZATION AND USE OF CRYPTIC HLA-B7 EPITOPES FOR IMMUNOTHERAPY - The present invention relates to the field of peptide immunotherapy. In particular, the invention pertains to a method for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, and to a method for increasing its immunogenicity. The invention also provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype. | 2011-10-20 |
20110256164 | VACCINE FOR THE PREVENTION OF BREAST CANCER RECURRENCE - Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods. | 2011-10-20 |
20110256165 | COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 2011-10-20 |
20110256166 | Multivalent vaccines comprising recombinant viral vectors - The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease. | 2011-10-20 |
20110256167 | IMMUNOSTIMULATING SAPONINS FOR USE IN SITU TUMOR-DESTRUCTION THERAPY - The present invention relates to pharmaceutical compositions for use in in situ tumor-destruction therapy comprising the steps of tumor destruction and administration of an immunostimulating amount of an immunopotentiator, and to the use of such pharmaceutical compositions in the manufacture of a medicament. | 2011-10-20 |
20110256168 | Conjugates that Contain the Homeodomain of Antennapedia - The subject invention pertains to a conjugate comprising: (a) a first region comprising the homeodomain of antennapedia or a variant thereof; and (b) a second region not naturally associated with the first region. In one embodiment, the second region of the conjugate comprises a protein of at least 100 amino acids. | 2011-10-20 |
20110256169 | NOVEL POLYPEPTIDES RELATED TO B-TYPE NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE - The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis. | 2011-10-20 |
20110256170 | Method For Increasing Performance of Offspring - Methods and compositions for increasing intestinal transport of nutrients or growth performance in the offspring of an animal are described. More specifically, a feed composition comprising an omega-3 fatty acid-containing composition for increasing intestinal transport of nutrients or growth performance in the offspring of the animal, and methods therefor, are described. | 2011-10-20 |
20110256171 | NOVEL USE OF L. UNDULATA EXTRACT AS THERAPEUTICS FOR ALLERGIC DISEASES - The present invention relates to a method of preventing or treating allergic diseases such as allergic rhinitis, atopic dermatitis, anaphylaxis, and asthma, which comprises administering an extract of | 2011-10-20 |
20110256172 | EPITOPE-TARGETED ANTHRAX VACCINE - Anthrax vaccine compositions comprise a segment of a PA toxin protein that stimulates a B cell immune response specific for a defined epitope on the protective antigen of | 2011-10-20 |
20110256173 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS - The efficient synthesis of phosphatidylinositol mono- to hexa-mannoside (PIM | 2011-10-20 |
20110256174 | RABIES VACCINE - An attenuated rabies virus for use as a vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the vaccine. | 2011-10-20 |
20110256175 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 2011-10-20 |
20110256176 | HERPES SIMPLEX VIRUS COMBINED SUBUNIT VACCINES AND METHODS OF USE THEREOF - This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention. | 2011-10-20 |
20110256177 | YERSINIA PESTIS VACCINE - The present invention encompasses a recombinant | 2011-10-20 |
20110256178 | BORRELLIA BURGDORFERI BACTERIN - A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated | 2011-10-20 |
20110256179 | PHARMACEUTICAL PREPARATION COMPRISING A COMBINATION OF STREPTOCOCCUS STRAINS AND LACTOBACILLUS STRAINS - A pharmaceutical preparation for prophylaxis against and treatment of | 2011-10-20 |
20110256180 | Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof - Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of | 2011-10-20 |
20110256181 | RECOMBINANT BACTERIUM CAPABLE OF ELICITING A PROTECTIVE IMMUNE RESPONSE AGAINST C. PERFRINGENS - The present invention encompasses recombinant bacteria and immunogenic compositions comprising the bacteria. The immunogenic composition may be used to induce an immune response against | 2011-10-20 |
20110256182 | GENES ENCODING MAJOR CAPSID PROTEIN L1 OF HUMAN PAPILLOMA VIRUS - The present invention discloses a codon-optimized gene encoding major capsid protein L1 of human papilloma virus, which is capable, after transduced into a yeast cell, of efficiently expressing the major capsid protein L1 of human papilloma virus. The present invention also discloses an immunogenic macromolecule which is essentially produced by expression of said codon-optimized gene encoding the major capsid protein L1 of human papilloma virus in a yeast cell. The present invention further discloses the use of said immunogenic macromolecule and a composition comprising said immunogenic macromolecule. | 2011-10-20 |
20110256183 | Hydrogels with network defects enhanced by nanoparticle incorporation - Compositions and methods are provided for the manufacture and use of hydrogels with increased permeability to macromolecules with minimum loss of matrix mechanical strength and prepolymer viscosity for patternability. The hydrogels of the invention are formed from a prepolymer, which is polymerized in the presence of hydrophobic nanoparticles. In some embodiments of the invention cells are present during polymerization, and are encapsulated by the hydrogel. A high interfacial energy between the hydrophobic substrate and the aqueous polymerizing solution disrupts the hydrogel network structure, leading to network defects that increase permeability without loss of patternability. | 2011-10-20 |
20110256184 | Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release - A non-ordered geometric mesoporous structure that provides for enhanced loading of antibodies such as IgG as compared to ordered mesoporous structures. This structure is formed by treating silica precursors at a hydrothermal aging temperature between 100 and 200 degrees C. This creates the non-ordered mesoporous structure. Biomolecules such as IgG can then be spontaneously loaded via non-covalent bonding within the as-made or functionalized mesoporous structure. | 2011-10-20 |
20110256185 | REINFORCED TISSUE SHIELDS - Self-reinforced tissue shields are useful as ophthalmic shields, wound dressings, wound barriers, nerve repair, therapeutic drug delivery devices and the like. The self-reinforced tissue protective shields comprise gelatin, chitosan and reinforce and are made by a method comprising forming inter-molecular locking within a solution through electrostatic forces, eliminating the use of extra cross-linking methods, the solution mainly comprising natural existing polymers that are biodegradable and biocompatible. | 2011-10-20 |
20110256186 | BIOMATERIAL BASED ON WHARTON'S JELLY FROM THE HUMAN UMBILICAL CORD - The present invention relates to a biomaterial, specifically a hydrogel, formed from the extracellular matrix of the umbilical cord for its application in regenerative medicine. The invention particularly relates to a biomaterial made up of glycosaminoglycans isolated exclusively from the Wharton's jelly of the umbilical cord which can optionally contain cells, and also to the methods for the production and use thereof. | 2011-10-20 |
20110256187 | BIOFILM-INHIBITORY COATINGS THAT RELEASE SALICYCLIC ACID BY HYDROLISIS - The present invention relates to coating compositions for modulating biofilm growth on a surface, the composition comprising the reaction product of:
| 2011-10-20 |
20110256188 | DRY POWDER PHARMACEUTICAL COMPOSITION FOR INHALATION - There is provided a dry powder pharmaceutical composition for inhalation useful for preventing and/or treating influenza virus infections contains as a medicinal component a compound represented by formula (I): | 2011-10-20 |
20110256189 | COATING MATERIAL FOR SOLID MEDICINE AND SOLID MEDICINE FORMED WITH SAME - A coating material for a solid formulation is capable of stably retaining the effective ingredient in the solid formulation for a prolonged period even in unpacked condition in such a manner that the solid formulation can be used in a single-dose formulation. The coating material for a solid formulation includes a high hydrogen-bonding resin and a swelling clay and, when coated on a solid formulation and dried, forms a coating film in which the laminated structures of the aforementioned swelling clay are oriented planarly and dispersed in a network fashion. | 2011-10-20 |
20110256190 | Modified release compositions comprising tacrolimus - A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents. | 2011-10-20 |
20110256191 | COMPOSITION - Leave-on hair care composition comprising an oil in water emulsion, the emulsion comprising a silicone gum of molecular weight of from 800 000 to 5 000 000 cSt, a nonionic or anionic polysaccharide and a low molecular weight solvent for the silicone gum. | 2011-10-20 |
20110256192 | PHOTOPROTECTIVE COMPOSITION CONTAINING AN UNMODIFIED GELLING STARCH AND POLYAMIDE PARTICLES - The present invention relates to a composition intended for protecting the skin and/or hair against ultraviolet radiation, characterized by the fact that it comprises, in a cosmetically acceptable support containing at least one aqueous phase, at least: (a) a photoprotective system capable of screening out UV radiation; (b) at least one gelling starch that is not modified by a chemical or physical process; and (c) polyamide particles, in particular polyamide PA-12 or polyamide PA-6 particles. The present invention also relates to the use of the combination of at least one gelling starch that is not modified by a chemical or physical process and polyamide particles in a composition comprising, in a cosmetically acceptable support comprising at least one aqueous phase, at least one photoprotective system capable of screening out UV radiation, for the purpose of improving the cosmetic properties after application, especially the non-tacky effect, non-greasy effect, non-shiny effect and/or the absence of residual film. | 2011-10-20 |
20110256193 | Use Of Copolymers Based On Polyethers And Vinyl Monomers As Stabilizing Agents For Emulsions - Use of water-soluble or water-dispersible copolymers which are obtained by polymerization of vinyl acetate and N-vinyllactams in the presence of a polyether, as stabilizing agents for emulsions. | 2011-10-20 |
20110256194 | PEARLESCENT PIGMENT - The present invention relates to a pearl pigment obtained by coating the surface of a flaky powder with a colored metal or a colored metal oxide and further coating the surface of the above colored metal- or colored metal oxide-coated flaky powder with a colorless metal or a colorless metal oxide, wherein when the pearl pigment is applied onto the surface of black artificial leather in an average amount of 0.05 mg/cm | 2011-10-20 |
20110256195 | INSECTICIDE-CONTAINING POLYMERIC MATERIAL - The present invention relates to an insecticide-containing polymeric material containing at least one embedded insecticidally active ingredient in the polymeric matrix and having excellent biological activity, and also to the products produced from this polymer and to their use for protecting humans, animals and plants against arthropods, particularly for controlling insects. | 2011-10-20 |
20110256196 | Insecticide for Bed Bugs - The present disclosure provides a method for killing arthropods. According to one embodiment of the present disclosure, the method preferably includes providing a pesticide composition which includes from about 0.01 to about 0.8 percent, by weight, of a surfactant and from about 0.2 to about 15 percent, by weight, of a boron-containing component. The pesticide composition is applied to a absorbent material which is infested with arthropods, so that the pesticide composition is adsorbed by the absorbent material in an amount sufficient to kill arthropods. The arthropods contact the absorbent material and are killed by the adsorbed pesticide composition. | 2011-10-20 |
20110256197 | Preparation of Metal Nanowire Decorated Carbon Allotropes - In the method of embodiments of the invention, the metal seeded carbon allotropes are reacted in solution forming zero valent metallic nanowires at the seeded sites. A polymeric passivating reagent, which selects for anisotropic growth is also used in the reaction to facilitate nanowire formation. The resulting structure resembles a porcupine, where carbon allotropes have metallic wires of nanometer dimensions that emanate from the seed sites on the carbon allotrope. These sites are populated by nanowires having approximately the same diameter as the starting nanoparticle diameter. | 2011-10-20 |
20110256198 | INSECTICIDE-CONTAINING NETLIKE FABRIC - The present invention relates to an insecticide-containing fabric containing at least one embedded insecticidally active ingredient in the polymeric matrix and having excellent wash resistance, and also to the products produced from this fabric and to their use for protecting humans, animals and plants against arthropods, particularly for controlling insects. | 2011-10-20 |
20110256199 | MELT EXTRUSION ENCAPSULATION OF FLAVORS AND OTHER ENCAPSULATES IN A CARRIER CONTAINING SPICES AND HERBS - Active encapsulation compositions which are stable in the glassy state at ambient temperatures are prepared by melt extrusion of a ternary carrier blend comprising of 1) a food polymer, 2) a spice or herb, and 3) a low molecular weight sugar or polyol. Such glassy matrices are useful for the encapsulation of encapsulates, in particular, flavors and medications. | 2011-10-20 |
20110256200 | PROCESS AND AQUEOUS FORMULATION FOR THE IMPREGNATION OF NON-LIVING-MATERIALS IMPARTING A PROTECTIVE ACTIVITY AGAINST PESTS - A process for the impregnation of non-living-materials comprises the step of impregnating the non-living material with an aqueous formulation free of organic solvents which comprises one or more pesticides and a polymeric binder comprising one or more fluorinated polyacrylates having a fluorine content (based on the solid content of the polymeric binder) of at least 10% by weight. | 2011-10-20 |
20110256201 | HYDROLYZED HYDROGELS - The invention provides methods of making hydrolyzed cross-linked polyvinyl alcohol (PVA) hydrogels by polymerizing vinyl acetate (VAc) monomers to polyvinyl acetate (PVAc) polymer network by chemical-crosslinking and hydrolysis. The invention also provides methods for including pendant chains in the hydrogel during the polymerization process. Materials produced and use of the cross-linked hydrolyzed PVA hydrogels also are disclosed herein. | 2011-10-20 |
20110256202 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 2011-10-20 |
20110256203 | POROUS CERAMIC SCAFFOLD HAVING AN ORGANIC/INORGANIC HYBRID COATING LAYER CONTAINING BIOACTIVE FACTOR AND METHOD THEREOF - A method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid composite coating layer containing a bioactive factor is disclosed. The method includes; forming a porous ceramic scaffold, mixing a silica xerogel and a physiologically active organic substance to prepare an organic/inorganic hybrid composite, adding a bioactive factor to the organic/inorganic hybrid composite, and filling the organic/inorganic composite containing the bioactive factor into a pore structure of the porous ceramic scaffold, thereby coating the porous ceramic scaffold. In accordance with the method, the porous ceramic scaffold may be uniformly coated with the organic/inorganic hybrid composite while maintaining an open pore structure, and stably discharge the bioactive factor over a long period of time. | 2011-10-20 |
20110256204 | RAPID PREPARATION AND USE OF ENGINEERED TISSUE AND SCAFFOLDS AS INDIVIDUAL IMPLANTS - Methods, technical apparatus and compositions to achieve short term processing for the manufacture of a graft or a transplant in the form of a scaffold that can be used to treat or to heal injuries and traumas of a great diversity of tissues and organs in a central or peripheral location of the human or an animal body. Tissue regeneration by way of stem cells and different specific tissue and organ repair promoting factors that activate the endogenous or exogenous stem cells to differentiate to specific tissue cells thus reconstituting the original microenvironment of the cell damaged by the injury. | 2011-10-20 |
20110256205 | Bone cell delivery device - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 2011-10-20 |
20110256206 | IMPLANTABLE DEVICES FOR TREATING HIV - The present invention relates to an implantable device comprising a biocompatible, biodegradable polymer mixed with TMC278 and with one or more release-enhancing agents selected from the group consisting of poloxamers, polysorbates, and a combination of dimethyl sulfoxide (DMSO) and poly(vinyl pyrrolidone)(PVP). | 2011-10-20 |
20110256207 | WHOLE GRAIN FLOUR AND PRODUCTS INCLUDING SAME - The present invention is a grain product. The grain product includes a first fraction including bran. The first fraction is milled to a first particle size of less than 500 micrometers. The grain product also includes a second fraction including germ. The second fraction is milled to a second particle size of less than 500 micrometers. The grain product is at least one of: a food product, a nutritional supplement, a dietary supplement, a fiber supplement, a digestive supplement, a functional food, and a medical food. | 2011-10-20 |
20110256208 | EDIBLE CARRIER FOR ANIMAL MEDICATION - An edible carrier for animal medication includes a main body with an accepting space and a cover, where the main body and cover are all made of an animal food material. The main body and cover respectively have annular first and second walls corresponding to each other, where the first wall and second wall respectively have a first engagement unit and second engagement unit corresponding to each other. Medicine may be placed in the accepting space, and the cover is then coupled to the main body fixedly by engaging the first engagement unit with the second engagement unit such that the medicine can be secured in the main body, and the carrier has a general shape and odor of animal food, and is mixed together with the food conveniently to feed animals, ensuring that animals cannot differentiate medicine from the food, thereby allowing animals to eat the medicine effectively. | 2011-10-20 |
20110256209 | Skin patch for improving menstrual - A patch and topical application for improving discomfort from menstruation includes soap scented oil mixed with vegetable oil, such as castor oil. | 2011-10-20 |
20110256210 | Transdermal Delivery - Dosing regimen for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval. | 2011-10-20 |
20110256211 | Transdermal Delivery - Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval. | 2011-10-20 |
20110256212 | Use of 8-Quinolinol and its Analogs to Target Cancer Stem Cells - 8-quinolinol (8Q) and derivatives thereof for use in the treatment of proliferative diseases such as cancer, in particular slow metabolizing quiescent cancer stem cells. | 2011-10-20 |
20110256213 | PHOSPHOLIPID MICELLAR AND LIPOSOMAL COMPOSITIONS AND USES THEREOF - The invention generally relates to compositions and methods for the reduction or neutralization of toxins associated with a bacterial, mycobacterial, fungal, viral, or protozoal agent. More particularly, the invention is directed to sterically stabilized phospholipid micellar and liposomal compositions, which interact with the toxins to decrease or neutralize their toxicity. Additionally, the invention includes the use of sterically stabilized phospholipid micellar compositions comprising one or more water-insoluble antibiotic, antifungal, antiviral, antiprotozoal, or anti-inflammatory agent(s), wherein the micellar or liposomal composition inhibits the formation of aggregates. The invention further includes the use of sterically stabilized micelle and liposomal compositions to deliver compounds to the site of action, and in some cases targets the compound to the site of action, for the treatment of inflammation and infection. The invention includes the use of combinations of such micellar and liposomal compositions to improve the effectiveness of treatment. | 2011-10-20 |
20110256214 | SINGLE-TIME VACCINES - The invention is related to the field of vaccines. The technical objective is to obtain novel unitemporal therapeutic and prophylactic vaccines (single time vaccination strategy) using simultaneously one or more mucosal doses and one parenteral dose where the use of potent mucosal adjuvants are essential, preferable the Cochleate (AFCo I, Adjuvant Finlay Cochleate 1). The incorporation or co-administration by parenteral and mucosal routes of non-related PL antigens (heterologous), and/or the additional use of delivery systems like Aluminum, Chitosan or oil/water emulsions by parenteral application is also included in this invention. The induction of cellular immune responses than including systemic specific IgG and secretory specific IgA is obtained with at least two simultaneously doses. So, this unitemporal strategy is applicable to obtaining new unique or multiples vaccines (several mucosal vaccine antigens with the corresponding parenteral combine vaccine) in the pharmaceutical industry which permit to increase vaccine coverage and reduce the time-cost of vaccine campaigns. | 2011-10-20 |
20110256215 | NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY - The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline. | 2011-10-20 |
20110256216 | Probiotic Confection and Lipid Compositions - The present application relates to probiotic confection-based compositions comprising lactic acid-producing bacteria and oil-based compositions comprising the same. | 2011-10-20 |
20110256217 | PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL DRUG ABSORPTION - Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a penetration enhancer which are released at a first location in the intestine, and a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix. This penetration enhancer is released at a second location in the intestine downstream from the first location and enhances absorption of the drug when it reaches the second location. | 2011-10-20 |
20110256218 | CONTROLLED RELEASE COMPOSITIONS COMPRISING MECLIZINE OR RELATED PIPERAZINE DERIVATIVES - The present invention provides pharmaceutically acceptable compositions for once-daily dosing comprising a piperazine derivative of H | 2011-10-20 |
20110256219 | Manufacturing Solid Pharmaceutical Dosage Forms With Visible Micro- And Nanostructured Surfaces And Micro- And Nanostructured Pharmaceutical Dosage Form - A solid pharmaceutical dosage form [ | 2011-10-20 |
20110256220 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 2011-10-20 |
20110256221 | PHARMACEUTICAL FORMULATIONS OF OLMESARTAN - This invention is related to pharmaceutical compositions, which have good flowability properties, comprising olmesartan medoxomil or combination of olmesartan medoxomil and hydrochlorothiazide and a lubricant or mixtures of lubricants and a pharmaceutically acceptable excipient or excipients. | 2011-10-20 |
20110256222 | Recombinant Protein Enriched in a Heparin Binding Site and/or in a Heparan Sulfate Binding Site - The invention relates to a recombinant protein enriched in a heparin binding site and/or a heparan sulfate binding site. Such recombinant protein is used as an in vivo controlled release system of a protein of interest. | 2011-10-20 |
20110256223 | GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 2011-10-20 |
20110256224 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY - The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of therapeutic agents. In one embodiment, these compositions are used for the tumor-targeted delivery of chemotherapeutic agents useful for treating cancer. | 2011-10-20 |
20110256225 | BIODEGRADABLE NANOPARTICLES AS NOVEL HEMOGLOBIN-BASED OXYGEN CARRIERS AND METHODS OF USING THE SAME - Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties. | 2011-10-20 |
20110256227 | CONTROLLED POLYPLEX ASSEMBLY - The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, polyplexes comprising polycations, polyanions, and polynucleotides are provided. The invention further provides methods of making and using said polyplexes. | 2011-10-20 |
20110256228 | Solid Forms for Tissue Repair Background of the Invention - This invention provides coral-based scaffolds for cartilage repair, and instruments for insertion and utilization of same within a site of cartilage repair. | 2011-10-20 |
20110256229 | RAPID-ACTING PHARMACEUTICAL COMPOSITION - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially insoluble or sparingly soluble in water, in combination with a bioadhesion and/or mucoadhesion promoting agent adhered to the surfaces of said carrier particles. The composition is primarily intended for sublingual or intranasal administration. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders. | 2011-10-20 |
20110256230 | WATER INSOLUBLE POLYMER: INDIGESTIBLE WATER-SOLUBLE POLYSACCHARIDE FILM COATINGS FOR COLON TARGETING - A controlled release pharmaceutical dosage form for controlled release of an active ingredient, includes an active ingredient coated by a polymeric mixture of: at least a water insoluble polymer; and at least an indigestible water-soluble oligosaccharide. The use and method of making the same are also described. | 2011-10-20 |
20110256231 | METHOD FOR PREPARING A MICRO-PARTICLE DRUG IN HEMISPHERE-SHAPED DOSAGE FORM AND APPLICATIONS THEREOF - A method for preparing drug in hemisphere-shaped dosage form. A high molecular weight solution containing the drug is prepared, and the solution is then dropped on a base material. The interface phenomena between the solution and different base materials makes the drop of high molecular weight solution containing the drug form a hemisphere-shape. After solidifying by cross-link or evaporation, the drug in hemisphere-shaped dosage form is obtained. The advantages of the preparation method are a simple and fast process, and simple operation. Applications of the method to prepare a drug in hemisphere-shaped dosage form are also provided. | 2011-10-20 |
20110256232 | ANTIMICROBIAL COMPOSITION FROM COPEPODS - The present invention relates to an antimicrobial composition, and to a process for the preparation of such a composition. The invention also relates to the use of such an antimicrobial composition. The present invention further relates to the use of the antimicrobial composition as a pharmaceutical. | 2011-10-20 |
20110256233 | HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - This disclosure features human milk permeates and compositions containing the same obtained from fractionated whole human milk The oligosaccharide rich permeate and permeate compositions of the present invention are useful as nutritional supplements for pre-term and full term infants, for establishing or maintaining gut flora and for treating the symptoms of inflammatory bowel disease. | 2011-10-20 |
20110256234 | CARRIER SYSTEM FOR SUBSEQUENT APPLICATION ONTO SUBSTRATES AND METHOD THEREFOR - A carrier system for transport of functional chemicals in substrates, such as fiber and plastic materials, comprises a carrier compound and at least one functional chemical, whereby the carrier compound consists of micelles, liposomes, lyotropic liquid crystals, or intercalation compounds. The functional chemical that is transported by the carrier compound migrates into the substrate and has an anisotropic distribution therein. Methods for modification, for activation and deactivation in a subsequent application on substrates are described. | 2011-10-20 |
20110256235 | COMPOSITIONS AND METHODS RELATING TO PREVENTION OF CHEMOTHERAPY-INDUCED ALOPECIA - The present invention relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective amount of a composition comprising a chemical inducer of the stress protein response sufficiently prior to the administration of a chemotherapeutic drug. It also relates to pharmaceutical compositions for the prevention of chemotherapy-induced alopecia. It further relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective heat dose sufficiently prior to the administration of a chemotherapeutic drug. | 2011-10-20 |
20110256236 | Enhancement of the Anti-Leukemic Effect of Thalidomide - The cytotoxic effects of thalidomide are enhanced when it is used in combination with other chemotherapeutic agents, particularly arsenic trioxide, indicating benefits for the treatment of blood-related cancers, especially acute myelogenous leukemia. | 2011-10-20 |
20110256237 | METHODS AND COMPOSITIONS FOR TREATING ACNE VULGARIS AND ACNE ROSACEA - Methods and compositions are described for treating acne vulgaris and acne rosacea by administering compositions suitable for oral administration. Suitable compositions contain high dosages of the vitamin nicotinamide combined with much lower dosages of azelaic acid. | 2011-10-20 |
20110256238 | WOOD PRESERVATIVE AND WOOD PROCESSING METHOD - The present invention relates to a wood preservative containing as an active ingredient 3′-isopropyl-2-trifluoromethyl benzoic acid anilide represented by the formula below and a wood treatment method using the same. The present invention can provide a wood preservative having excellent preservation effect on various wood-destroying fungi with a very small chemical dosage and a wood treatment method, which are economical and have a small environmental load. | 2011-10-20 |